Vidipha Central Pharmaceutical JSC

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: VN000000VDP2
VND
54,000.00
-900 (-1.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Vidipha Central Pharmaceutical JSC

Why is Vidipha Central Pharmaceutical JSC ?

1
Flat results in Sep 25
  • ROCE(HY) Lowest at 8.37%
  • INTEREST(Q) At VND 3,135.14 MM has Grown at 26.15%
  • RAW MATERIAL COST(Y) Grown by 45.94% (YoY)
2
With ROE of 9.08%, it has a fair valuation with a 0.00 Price to Book Value
  • Over the past year, while the stock has generated a return of 39.47%, its profits have risen by 0.1%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vidipha Central Pharmaceutical JSC for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Vidipha Central Pharmaceutical JSC
56.52%
1.13
44.43%
Vietnam VN Ho Chi Minh Index
38.87%
1.90
22.90%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
11.58%
EBIT Growth (5y)
10.05%
EBIT to Interest (avg)
4.71
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.97
Tax Ratio
20.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.37%
ROE (avg)
10.13%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
-1.81
EV to EBITDA
-1.29
EV to Capital Employed
-0.22
EV to Sales
-0.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
8.28%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
OPERATING CASH FLOW(Y)

Highest at VND 269,394.6 MM

RAW MATERIAL COST(Y)

Fallen by 0.88% (YoY

CASH AND EQV(HY)

Highest at VND 815,664.3 MM

DEBT-EQUITY RATIO (HY)

Lowest at -27.72 %

-11What is not working for the Company
NET SALES(HY)

At VND 352,762.71 MM has Grown at -31.9%

ROCE(HY)

Lowest at 7.38%

PRE-TAX PROFIT(Q)

Lowest at VND 14,959.38 MM

NET PROFIT(Q)

Lowest at VND 11,917.59 MM

EPS(Q)

Lowest at VND 539.66

Here's what is working for Vidipha Central Pharmaceutical JSC

Operating Cash Flow
Highest at VND 269,394.6 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (VND MM)

Cash and Eqv
Highest at VND 815,664.3 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -27.72 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0.88% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vidipha Central Pharmaceutical JSC

Net Sales
At VND 352,762.71 MM has Grown at -31.9%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (VND MM)

Pre-Tax Profit
Lowest at VND 14,959.38 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (VND MM)

Net Profit
Lowest at VND 11,917.59 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (VND MM)

EPS
Lowest at VND 539.66
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (VND)